UNSPSC 41131732: Partial thromboplastin time tests

In this classification a partial thromboplastin time test is a device used for primary screening for coagulation abnormalities, for evaluation of the effect of therapy on procoagulant disorders, and as an assay for coagulation factor deficiencies of the intrinsic coagulation pathway US FDA regulates Partial thromboplastin time tests under 21 CFR 864.7925 and under FDA product code GFO.

UNSPSC 41131732 Partial thromboplastin time tests is a Commodity-tier code, but the recent state and local opportunities show little activity aligned with this code's nominal scope. The handful of posted solicitations fall primarily into offender and employment drug testing, forensic drug standards for laboratory analysis, breath alcohol testing equipment procurement, and naloxone distribution—none of which constitutes partial thromboplastin time (PTT) testing, a coagulation assay used in clinical hematology. The only opportunity with potential relevance to laboratory testing methodology is Benton County, Oregon's urinalysis testing RFP for its Family Treatment Court Program, which calls for CLIA-certified laboratory services with immunoassay and confirmatory testing, but even this addresses drug screening rather than PTT analysis. The code shows no meaningful recent procurement activity within state and local government that reflects its actual clinical laboratory testing purpose.

The geographic spread of posted opportunities spans Florida (Seminole County, Collier County, Pinellas County, Clay County), Oregon (Benton County and the State of Oregon), Texas (Collin County), Illinois (City Colleges of Chicago), and Nevada (State Department of Public Safety), but these solicitations are concentrated in criminal justice, occupational health, and forensic applications—drug testing, employment physicals, and breath alcohol equipment—rather than clinical coagulation testing. Collin County's offender specimen collection and drug testing RFP (due July 23, 2026) represents the largest identified opportunity at $600,000 estimated value over two years with three optional renewals, but it addresses five- and six-panel immunoassay drug screening and confirmation testing. Clay County's IFB for physicals and drug testing (due February 26, 2026) and Benton County's urinalysis testing RFP (due July 6, 2026) follow similar patterns. Until state and local procurement offices begin posting opportunities for actual PTT testing services or clinical laboratory coagulation analysis, this code remains inactive for business development purposes in the state and local marketplace.